<DOC>
	<DOCNO>NCT02252042</DOCNO>
	<brief_summary>This study pembrolizumab ( MK-3475 , KEYTRUDAÂ® ) versus standard treatment ( methotrexate , docetaxel cetuximab ) treatment recurrent metastatic head neck squamous cell cancer ( HNSCC ) . Participants randomly assign receive either pembrolizumab Investigator 's choice standard treatment . The primary study hypothesis pembrolizumab treatment prolongs overall survival compare standard treatment .</brief_summary>
	<brief_title>Pembrolizumab ( MK-3475 ) Versus Standard Treatment Recurrent Metastatic Head Neck Cancer ( MK-3475-040/KEYNOTE-040 )</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Has histologically cytologicallyconfirmed recurrent disease amenable curative treatment local systemic therapy , metastatic ( disseminate ) head neck squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx consider incurable local therapy Failure prior platinum therapy Radiographicallymeasurable disease base RECIST 1.1 Tumor tissue available PDL1 biomarker analysis Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate organ function Female participant childbearing potential must willing use 2 method birth control abstain heterosexual activity course study 120 day last dose pembrolizumab 120180 day last dose docetaxel , methotrexate cetuximab , acccording local standard care Male participant must agree use adequate method contraception start first dose study therapy 120 day last dose pembrolizumab 120180 day last dose docetaxel , methotrexate cetuximab , acccording local standard care Exclusion Criteria Disease suitable local therapy administer curative intent Currently participate participate study investigational agent use investigational device within 4 week prior randomization Previously treat 3 systemic regimen give recurrent and/or metastatic disease Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study therapy Not recovered adverse event due therapy 4 week earlier Prior anticancer monoclonal antibody ( mAb ) therapy within 4 week prior study Day 1 , recover adverse event due agent administer 4 week earlier Prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 Diagnosed and/or treat additional malignancy within 5 year randomization , exception curativelytreated basal cell squamous cell carcinoma skin , and/or curativelyresected situ cervical and/or breast cancer Active autoimmune disease require systemic therapy past 2 year modify agent , corticosteroid , immunosuppressive agent Active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Active , noninfectious pneumonitis Active infection require systemic therapy Pregnant , breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day last dose trial therapy accord local standard care Prior therapy antiPD1 antiPD1L1 L2 therapy previously participate Merck pembrolizumab ( MK3475 ) trial Human immunodeficiency virus ( HIV ) Hepatitis B C Live vaccine within 30 day plan start study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Squamous cell carcinoma</keyword>
	<keyword>Head neck carcinoma</keyword>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>